Fosun Pharma: Controlling subsidiary's drugs included in breakthrough therapy program.

Fosun Pharma announced that its FCN-159 tablet for the treatment of children with Langerhans cell histiocytosis has been included in the breakthrough therapy drug program. This new drug is a selective MEK1/2 inhibitor, intended primarily for the treatment of advanced solid tumors, type 1 neurofibromatosis, dendritic cell and histiocytic tumors, low-grade gliomas, etc. As of April 2025, the cumulative research and development investment for this new drug by the group is approximately RMB 5.98 billion. According to Chinese regulations, this new drug still needs to undergo a series of clinical studies in China and obtain approval from the national drug regulatory department before it can be marketed.